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Abstract
Background: Retinal imaging may serve as an alternative approach to monitor brain pathology in Alzheimer’s
disease (AD). In this study, we investigated the association between retinal vascular and structural changes and
cerebral amyloid-β (Aβ) plaque load in an elderly cohort.
Methods: We studied a total of 101 participants, including 73 elderly subjects (79 ± 5 years, 22 male) with no clinical
diagnosis of AD but reporting some subjective memory change and an additional 28 subjects (70 ± 9 years, 16 male)
with clinically established AD. Following a complete dilated ocular examination, the amplitude of retinal vascular
pulsations and dynamic response, retinal nerve fibre layer thickness and retinal ganglion cell layer (RGCL) thickness
were determined in all patients. Systemic blood pressure and carotid-to-femoral pulse wave velocity were measured.
The elderly cohort also underwent magnetic resonance imaging and 18F-florbetaben (FBB)-positron emission
tomographic amyloid imaging to measure neocortical Aβ standardised uptake value ratio (SUVR), and this was
used to characterise a ‘preclinical’ group (SUVR >1.4).
Results: The mean FBB neocortical SUVR was 1.35 ± 0.3. The amplitude of retinal venous pulsations correlated
negatively with the neocortical Aβ scores (p < 0.001), whereas the amplitude of retinal arterial pulsations correlated
positively with neocortical Aβ scores (p < 0.01). RGCL thickness was significantly lower in the clinical AD group (p < 0.05).
Conclusions: The correlation between retinal vascular changes and Aβ plaque load supports the possibility of a vascular
component to AD. Dynamic retinal vascular parameters may provide an additional inexpensive tool to aid in the
preclinical assessment of AD.
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Background
Alzheimer’s disease (AD) is the most common form of
dementia, accounting for 60–70% of all dementia cases.
AD is a progressive neurodegenerative disorder causing
irreversible deterioration in cognitive function secondary
to neuronal cell death and brain atrophy [1]. The main
pathological features are the accumulation of two proteins:
amyloid-β (Aβ) peptide, generated from its parent mole-
cule, the amyloid precursor protein (APP), which aggre-
gates into extracellular plaques, and hyper-phosphorylated
tau, which forms intracellular neurofibrillary tangles [2].
Evidence now implies that neuropathological changes in-
volving the accumulation of Aβ occur up to 20 years prior
to the emergence of clinical symptoms, emphasising the
importance of developing methods for early diagnosis [3].
Currently, diagnosis is based primarily upon cognitive
assessments of patients presenting with symptomatic
features of cognitive and behavioural change [4, 5]. On
the basis of these assessments, an individual may fall
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into one of three categories: (1) probable AD dementia,
(2) possible AD dementia or (3) probable or possible AD
dementia with evidence of the AD pathophysiological
process [5]. Computed tomography and/or magnetic
resonance imaging (MRI) are frequently used clinically
in the initial diagnosis of cases where probable AD is
likely, whereas positron emission tomographic (PET)
amyloid imaging is less frequently included where con-
firmation is needed; however, this is not universal [6].
Johnson and colleagues [7] devised a set of criteria that
an individual must meet before PET amyloid imaging
can be considered ‘appropriate’. These criteria include
(1) a cognitive complaint, (2) possible AD diagnosis and
(3) whether the knowledge of the presence or absence of
Aβ will increase diagnostic accuracy or certainty. How-
ever, PET is not applicable for use in population-wide
screening, owing to the relatively high cost of this test.
Besides PET amyloid imaging, cerebrospinal fluid (CSF)
pathophysiological markers, including Aβ1–42, total tau
and phosphorylated Tau, have also shown high specifi-
city in confirming AD pathophysiology [4].
Because the retina is considered an extension of the
central nervous system (CNS) via the optic nerve, re-
searchers have investigated it to determine whether it can
serve as a marker for AD change [8]. The advantages of
including the retina in investigations for diagnosing prob-
able AD include its low cost, easy accessibility and the
non-invasive nature of the tests. Recently, researchers
have identified Aβ deposits in eyes from both human AD
and transgenic mouse models. Retinal imaging techniques
for Aβ are being investigated for detection of potential
biomarkers for preclinical AD [9]. Although human stud-
ies have identified retinal abnormalities in patients with
AD, such as reduced retinal nerve fibre layer (RNFL)
thickness [10] and degeneration of retinal ganglion cells
[11], these deficits are not AD-specific and are seen in pa-
tients with other degenerative diseases, such as glaucoma
[12]. Animal models including APP/PS1-transgenic mice
show Aβ plaques depositing in the retina, and these
plaques have been correlated with plaque load in the brain
[1]. The investigators in the latter study also reported de-
tecting the amyloid burden in the retina at 2.5 months of
age, which preceded the brain deposition occurring from
5 months of age.
Researchers have also identified a potential association
between changes in vascular parameters, both static and
dynamic, and AD changes. These include retinal vessel
diameter [13, 14] as well as systemic cardiovascular mea-
surements of blood pressure and pulse wave velocity
(PWV) [15, 16]. Amyloid plaques have been reported to
be closely located to blood vessels in the brain [17]. Sys-
temic changes in parameters such as increased blood
pressure [15] and arterial stiffness [16] have been corre-
lated with declining cognition. In APP/PS1-transgenic
mice, increased blood pressure was associated with
higher concentrations of Aβ plaques in the brain. In
addition, endothelial cell function includes regulation of
APP, which could support the concept of increased
mechanical stress as a contributing factor in the over-
production of Aβ in the vasculature.
Therefore, in this study, we aimed to determine if there
was an association between retinal vascular parameters
and neocortical Aβ concentrations. Vascular changes and
PET amyloid scan results were documented in an elderly
group of participants who had subjectively reported some
memory issues but had no clinical signs of AD confirmed
in testing. Vascular changes identified were then also in-




A total of 101 participants were included. Of these, 73
subjects (22 males, aged 79 ± 5 years) had no clinical
signs of AD dementia, referred to as the elderly cohort,
and 28 patients (16 males, aged 70 ± 9 years) had clinic-
ally diagnosed disease, referred to as the clinical AD co-
hort. All participants were examined in the Macquarie
University Eye Clinic, where a complete medical history
was taken and an eye examination was performed,
including visual acuity, slit-lamp examination and intra-
ocular pressure (IOP) with Goldmann tonometry. Tropi-
camide 1% was instilled to dilate pupils. The RNFL and
retinal ganglion cell layer (RGCL) thicknesses were
measured using spectral domain optical coherence tom-
ography (OCT) (Nidek Co., Gamagori, Japan). The am-
plitudes of retinal vascular pulsations were measured
using the Dynamic Vessel Analysis system (Imedos, Jena
Germany). Following the ocular tests, all participants
visited the Macquarie Heart Clinic (Sydney, Australia)
for blood pressure and PWV measurements.
Elderly cohort
Seventy-three participants were residents from the
Anglican Retirement Villages (ARV) across three loca-
tions in Sydney. These individuals were participants in
the Kerr Anglican Retirement Villages Initiative in
Ageing Health (KARVIAH) study, which required them
to undertake Aβ-PET imaging. Participants who had re-
ported any subjective memory complaints but were cog-
nitively healthy with no confirmation of dementia by
objective neuropsychological assessments were recruited.
Inclusion criteria for the study included (1) aged 65–90
years, with good health and no significant cerebrovascular
disease; (2) living in independent living units or similar ac-
commodations; (3) English speaker; (4) adequate vision
and hearing to enable testing; (5) memory complaint as
determined by Memory Complaint Questionnaire and
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preferably corroborated by an informant; (6) no objective
memory impairment (based on cognitive test scores); (7)
normal general cognitive function as determined by a
Montreal Cognitive Assessment score greater than or
equal to 26 during screening; (8) no significant functional
impairments/behaviour problems as indicated by the
Informant Questionnaire on Cognitive Decline in the
Elderly and the 36-item Short Form Health Survey; and
(9) intact activities of daily living (ADL) (i.e., no or min-
imal impairment in ADLs as determined by a clinical
interview). Of the 73 participants, 8 (11%) had glaucoma,
5 (7%) had macular degeneration, 41 (56%) had systemic
hypertension and were on monotherapy, 7 (10%) had non-
insulin-dependent diabetes, 6 (8%) had a history of transi-
ent ischaemic attack (TIA) but not confirmed stroke, 5
(7%) had ischaemic heart disease (IHD) and 22 (30%) were
past smokers. The subjects visited Macquarie Medical
Imaging for neuroimaging, including PET and MRI scans.
Within 6 weeks of undergoing imaging, the subjects
returned to Macquarie Eye Clinic for their ocular
examinations.
Clinical AD cohort
A further 28 participants diagnosed with AD were re-
ferred by Macquarie Neurology. The clinical AD cohort
had inclusion/exclusion criteria similar to those of the
elderly cohort, and they all underwent the neuro-
psychological battery used in the Australian Imaging,
Biomarkers and Lifestyle (AIBL) study of ageing to
confirm clinical AD [18].
Optical coherence tomography and vascular imaging
All participants underwent retinal OCT. The scans in-
cluded a peri-papillary RNFL scan and a 9-mm × 9-mm
macular scan to determine RGCL complex.
The technique used for measuring retinal vascular
pulsation and dynamic vascular response has been de-
scribed previously [19]. In brief, a digital camera was
used to capture retinal images during a short video re-
cording. The recording duration was 180 seconds during
which three sets of flicker-induced light stimulated the
retina, with each cycle lasting 30 seconds. The retinal
image is registered by the software, and video analysis
can then be performed, minimising effects of eye move-
ment. Individual arteries and veins at four quadrant
locations near the nerve were selected for analysis, and
the vascular dilatory response of the vessels in response
to flicker was recorded. The amplitude of vessel pulsati-
lity was also determined for both arteries and veins.
Systemic vascular measurements
The participants were seated, and a standard cuff was
placed around the upper arm over the brachial artery to
measure blood pressure. Two consistent measurements
with no more than 5-mmHg difference between the sys-
tolic values were taken and recorded. The subjects then
lay supine for carotid-to-femoral PWV measurements to
assess peripheral arterial stiffness. A cuff was placed
around the femoral artery, and a tonometer sensor was
positioned on the carotid pulse. Distances were mea-
sured from the cuff to the femoral artery, the cuff to the
sternal notch, and the carotid artery to the sternal notch
to calculate the time difference from the carotid artery
to the femoral artery using the SphygmoCor system
(AtCor Medical, West Ryde, Australia).
Neuroimaging
MRI consisted of three-dimensional, T1-weighted,
magnetisation-prepared rapid gradient echo scans
(repetition time 2.3 milliseconds, echo time 2.98 milli-
seconds and flip angle 9 degrees). Following MRI,
radiolabelled 18F-florbetaben was used for the PET
amyloid scans. Participants were administered 1.6 ±
1.2 μg of florbetaben with a specific activity of 105 ±
74 GBq/μmol and radiochemical purity higher than
95%. PET amyloid imaging was then performed. A trans-
mission scan using a rotating 137Cs source was obtained
for attenuation correction immediately before the emis-
sion scan.
Data analysis
Retinal and florbetaben-PET analyses were performed
blinded to each other and to other study data. We proc-
essed the PET-FBB images and quantified the retention
by the standardised uptake value ratio (SUVR), which is
the standardised uptake value normalised by the average
uptake in the cerebellum as a reference. The SUVR of
the neocortex was computed as the average SUVR in the
grey matter masked neocortical region composed of the
frontal, superior parietal, lateral temporal, occipital, and
anterior and posterior cingulate regions using Computa-
tional Analysis of PET from AIBL image-processing
software(CapAIBL; https://capaibl-milxcloud.csiro.au/).
For further analysis, subjects with a cut-off value greater
than 1.4 were then categorised as the preclinical AD
group, and participants with a cut-off less than 1.4 were
designated as the elderly control group [20]. Neocortical
Aβ was expressed as the average SUVR for the regions
of interest (ROIs). The ROIs included frontal, superior
parietal, lateral temporal, lateral occipital, and anterior
and posterior cingulate regions. For a within-group ana-
lysis, all measured parameters were assessed for the pre-
clinical group (neocortical amyloid load [NAL] ≥1.4) and
the elderly control group (NAL <1.4). The vascular
imaging data were analysed by extracting a 20-second
window of recording with the highest signal-to-noise ra-
tio selected and then passing it through a low-pass filter
with a cut-off frequency of 3 Hz. Peaks and troughs of
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the signal were detected using spike software (Cam-
bridge Electronic Design, UK) [19], and the difference
between these was designated as the pulse amplitude.
RNFL, macular thickness and pulsatility of vessels were
compared with the SUVR values using analysis of vari-
ance (ANOVA) and post hoc analysis between high and
low NAL values. Linear regression was then applied to
assess the relationships between the vascular imaging
and OCT measurements across all subjects, as well as
the systemic measurements. Adjustments were made for
age, where necessary, before analysis. Prism software
(GraphPad Software, La Jolla, CA, USA) was used for all
statistical analyses.
Results
Participant demographics are shown in Table 1. All co-
horts had similar characteristics, except for a much
higher proportion of females in the elderly and preclini-
cal AD groups. Adjustments for age did not statistically
alter the end results.
Retinal vascular parameters
The amplitude of retinal arterial pulsations (RAP) was
assessed and analysed across the three subgroups: (1)
participants with an NAL less than 1.4 (n = 50), the
elderly control group; (2) participants with an NAL
greater than 1.4 (n = 23), the preclinical AD group; and
(3) the clinical AD group (n = 28), with the assumption
that this group would have an Aβ SUVR greater than 2
[20] (assuming that the diagnosis was 100% accurate,
though in clinical practice this figure is around 80%).
The mean RAP values across these three groups were
4 ± 1.2 μm, 5.2 ± 1.2 μm and 4.6 ± 1 μm, respectively.
One-way ANOVA revealed a significant difference
across the three groups (p = 0.001). Post hoc multiple
comparisons revealed that there were significant differ-
ences between groups 1 and 3 (p = 0.03) and between
groups 1 and 2 (p = 0.006), but no significant difference
between groups 2 and 3 (p = 0.14) (Fig. 1a). The
association between RAP amplitude and neocortical Aβ
SUVR in the grouped control and preclinical AD cohort
was assessed using linear regression. A positive association
between the two was observed (p = 0.01, r = 0.33) (Fig. 1b).
RAP amplitude was significantly higher in the preclinical
group than in the elderly control subjects. When we
added the data from the clinical AD group, the trend did
not continue. However, the difference in RAP between
preclinical and clinical AD was non-significant. Also, we
expect that the RAP trend might have continued to in-
crease if we had the actual Aβ SUVR for this group.
A similar approach was taken when we analysed the amp-
litude of retinal venous pulsations (RVP). The mean RVP
values across these three groups were 5.8 ± 1 μm, 5.2 ±
1 μm and 4.9 ± 1.2 μm, respectively. One-way ANOVA
revealed a significant difference across the three groups
(p = 0.004). Post hoc multiple comparisons revealed that
there were significant differences between groups 1 and 3
(p = 0.006) and between groups 1 and 2 (p = 0.03), but no
significant difference was observed between groups 2 and
3 (p = 0.37) (Fig. 2a). The association between amplitude
of RVP and neocortical Aβ SUVR in the grouped control
and preclinical AD cohort was assessed using linear
regression. A negative association between the two was
observed (p = 0.003, r = 0.4) (Fig. 2b).
Flicker-induced retinal vasodilation
We also assessed flicker light-induced retinal vasodila-
tion. Table 2 shows the mean vasodilation percentages
in the control (NAL <1.4), preclinical (NAL ≥1.4) and
clinical AD cohorts. Although the mean retinal arterial
and venous dilation was slightly lower in the preclinical
group than in the control subjects, we did not observe
any statistically significant difference (p = 0.39). The rela-
tionship between neocortical Aβ SUVR and retinal arter-
ial and venous dilation, assessed by linear regression,
was also non-significant (p = 0.1).
Retinal structural measurements
The average RNFL thickness across the three groups
(i.e., control subjects [NAL <1.4], preclinical AD [NAL
≥1.4] and clinical AD) was 93 ± 18 μm, 101 ± 15 μm and
99 ± 17 μm, respectively. We did not observe a signifi-
cant difference in RNFL thickness between the three
groups (p > 0.05). The association between the amplitude
of RNFL thickness and neocortical Aβ SUVR in the
grouped control and preclinical cohort was also not
significant (p > 0.05). The average RGCL thicknesses
across the three groups were 96 ± 9 μm, 98 ± 9 μm and
91 ± 2 μm, respectively. A significant difference in
RGCL thickness across the three groups was observed
(p = 0.02). Post hoc multiple comparisons revealed that
there were significant differences between groups 1 and
3 (p = 0.03) and between groups 2 and 3 (p = 0.005), but










Males/females 14/36 9/14 16/12
Mean age, years 79 ± 5 80 ± 4 70 ± 9
Mean IOP, mmHg 14 ± 3 13 ± 3 13 ± 3
Mean SBP, mmHg 153 ± 14 142 ± 18 137 ± 17
Mean DBP, mmHg 83 ± 15 77 ± 18 80 ± 8
Mean Aβ, SUVR 1.17 ± 0.09 1.75 ± 0.24 –
Abbreviations: Aβ Amyloid-β, AD Alzheimer’s disease, DBP Diastolic blood
pressure, IOP Intra-ocular pressure, NAL Neocortical amyloid load, SBP Systolic
blood pressure, SUVR Standardised uptake value ratio
Golzan et al. Alzheimer's Research & Therapy  (2017) 9:13 Page 4 of 9
no significant difference was observed between groups
1 and 2 (p = 0.7) (Fig. 3a). The association between
RGCL thickness and neocortical Aβ SUVR in the
grouped control and preclinical cohort, as assessed by
linear regression, was also not significant (p = 0.27).
Collectively, there was only a small degree of retinal
structural changes identifiable with OCT, and this was
found only in the RGCL analysis.
Systemic vascular parameters
We also investigated for differences in systemic cardiovas-
cular parameters between the subgroups. Pulse pressure
(PP = systolic blood pressure − diastolic blood pressure)
and PWV were assessed. The average PP and PWV across
the three groups were, respectively, 68 ± 13 mmHg, 8.8 ±
1.4 m/second; 65 ± 12 mmHg, 8.7 ± 1.5 m/second; and
67.4 ± 13.3 mmHg, 8.8 ± 1.4 m/second. There was no
significant association between PP, PWV and neocortical
Aβ SUVR in the grouped control and preclinical cohort
(p = 0.4) across all subjects. Subgroup analysis also did
not reveal any significant difference (p = 0.3) between
PP, PWV and neocortical Aβ SUVR in the elderly sub-
jects vs the preclinical AD group.
Finally, we applied an analysis of covariance to investi-
gate whether co-morbidities including hypertension,
diabetes, TIA, IHD and a history of smoking influenced
the association between RVP, RAP and Aβ SUVR. The
results showed that the differences between the slopes
were not significant (p > 0.05).
Discussion
In this study, we investigated the association between
retinal haemodynamics and cerebral Aβ load in a cohort
of elderly participants with no clinical diagnosis of AD
but who had subjective memory complaints, and we
subdivided these for further analysis according to PET
scan results (elderly control subjects [NAL <1.4], pre-
clinical AD [NAL ≥1.4]). Participants with confirmed
clinical signs of AD were also included to replicate the
trend observed in our preclinical AD cohort. We ob-
served a negative correlation between amplitude of RVP
and Aβ SUVR in the preclinical cohort. The correlation
was positive when we compared RAP amplitude and Aβ
Fig. 1 Association between retinal arterial pulsations (RAP) and standardised uptake value ratio (SUVR). Left: Mean and SD of RAP across control
subjects, preclinical Alzheimer’s disease (AD) and clinical AD. Right: Linear association between RAP and SUVR obtained from control subjects and
participants with preclinical AD
Fig. 2 Association between retinal venous pulsations (RVP) and standardised uptake value ratio (SUVR). Left: Mean and SD of RVP across control
subjects, preclinical Alzheimer’s disease (AD) and clinical AD. Right: Linear association between RVP and SUVR obtained from control subjects and
participants with preclinical AD
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SUVR. When data from our clinical AD cohort were
added for comparison, with the assumption that these
patients would have an Aβ SUVR greater than 2.0 [20],
we observed a continuing trend in our control subjects
and preclinical AD cohort, further supporting the as-
sociation between retinal haemodynamics and cerebral
Aβ load.
Recent studies have shown a significant association
between measures of vascular function (PP, arterial stiff-
ness, endothelial function, carotid intima-media thick-
ness, endothelial cell response to stress) and cognitive
function [16, 21, 22]. Mechanical forces on endothelial
cells result in activation of a range of cell-signalling
pathways as well as alterations in cell morphology, cell
function and gene expression [23]. In contrast, effects of
dynamic forces due to pulsatile pressure and flow result
in cyclic strain on the cell membrane. Cyclic stretch has
also been shown to induce retinal expression of vascular
endothelial growth factor and has been implicated in the
exacerbation of diabetic retinopathy by high blood pres-
sure [24].
Recent studies have highlighted the link between
endothelial nitric oxide (NO) and cerebrovascular func-
tion, in modulation of the processing of APP, in affecting
the functional status of microglia, and on cognitive func-
tion [25]. Loss of NO in cultured human cerebrovascular
endothelium has been shown to increase the expression of
APP and β-site amyloid precursor protein-cleaving en-
zyme 1 (BACE1), thereby resulting in increased secretion
of Aβ peptides (Aβ1–40 and Aβ1–42) [26]. Increased expres-
sion of APP and BACE1, as well as increased production
of Aβ peptides, was also detected in the cerebral micro-
vasculature and brain tissue of endothelial nitric oxide
synthase-deficient mice.
Collectively, the higher retinal arterial pulse ampli-
tude observed may be due to mechanical cyclic stretch
(to simulate the mechanical pulsatile effect of arterial
pressure) in response to upregulation of APP expres-
sion as well as deposition of Aβ plaques. Further studies
are required to elucidate underlying mechanisms involved
in regulating retinal arterial pulse amplitude in AD. It may
be a primary risk factor, or it may occur secondary to local
endothelially induced changes.
With respect to static retinal imaging, many researchers
have investigated the correlation between retinal vascular
calibre and cognitive decline [27–29]. However, the limita-
tion with static measures is that often the biomarkers
observed are not specific to the disease and can be
seen in other diseases that may affect retinal pathology
(e.g., hypertension, diabetes). In the Rotterdam study,
researchers reported that larger retinal venular calibres
were associated with an increased risk of dementia
[30]. These findings are contradictory to those of an-
other study in which investigators reported that nar-
rower venular calibre is associated with likeliness of
AD development [28]. In our cohort, we did not ob-
serve any significant association between retinal ven-
ous and arterial diameters with Aβ SUVR. However,
studying dynamic indices of retinal vessels, including
retinal pulsatility and local arterial PWV, within retinal
vessels (a measure of arterial stiffness) is more likely to
be applicable in identifying those at risk.
In this study, we also investigated endothelial dysfunc-
tion in retinal vasculature and its association with neo-
cortical Aβ scores. Endothelial dysfunction plays a
significant role in the pathogenesis of vascular abnor-
malities, and various feedback mechanisms are involved
Table 2 Flicker-induced retinal vasodilation
Arterial dilation (%) Venous dilation (%)
Elderly control group
(NAL <1.4)
2.4 ± 1 3.1 ± 1.2
Preclinical group
(NAL ≥1.4)
2 ± 1.1 3 ± 1.5
Clinical AD 2.7 ± 0.5 2.8 ± 1
AD Alzheimer’s disease, NAL Neocortical amyloid load
Fig. 3 Association between retinal ganglion cell layer (RGCL) thickness and standardised uptake value ratio (SUVR). Left: Mean and SD of RGCL
thickness across control subjects, participants with preclinical Alzheimer’s disease (AD) and participants with clinical AD. Right Linear association
between RGCL thickness and SUVR obtained from control subjects and participants with preclinical AD
Golzan et al. Alzheimer's Research & Therapy  (2017) 9:13 Page 6 of 9
in retinal autoregulation. Previous studies have demon-
strated that NO is involved in retinal vasodilation during
flicker light stimulation [31, 32]. Although we observed
significantly lower vasodilation in retinal arteries and
veins in the clinical AD cohort in comparison with the
participants having an Aβ SUVR less than 1.4, we did
not see any significant association between the percent-
age of retinal vasodilation during flicker stimulation and
Aβ SUVR.
The origin of spontaneous RVP in the eye is debated,
with some researchers suggesting abnormalities in the
ocular perfusion pressure in combination with high cen-
tral retinal vein pressures as the main factor [33–35],
whereas others argue for an imbalance in translaminar
pressure gradient across the lamina cribrosa (IOP-CSF
pressure) [36, 37]. Lower venous pulsations are also ob-
served in primary open angle glaucoma [38]. Glaucoma
and AD share common features of age-related risk,
chronic decline in function and focal degeneration of
neurons. Both diseases are characterised as degenerative
disorders involving the CNS, and even though glau-
coma is primarily an optic nerve disorder, secondary
changes have been observed in the radiations and visual
cortex. Glaucoma has been reported to be associated
with AD pathophysiology [39, 40]. There are also re-
ports suggesting that glaucoma prevalence is higher in
AD (2.6 to 5.2 times) [41]; both diseases are associated
with microbleeding [42, 43]. In our cohort, we did find
a higher-than-average incidence of subjects with glau-
coma (8 of 73 [about 11%]), but subanalysis did not
identify this group of participants as showing any sig-
nificant difference in parameters other than thinner
RGCL/RNFL, as expected.
Retinal structural changes, including RNFL and RGCL
thickness, have been reported in AD [44–46]. Although
most reports of thinning of RNFL and GCL are associ-
ated with AD severity, some suggest a non-significant
correlation between retinal structures and AD severity
[45, 47]. Our findings show a non-significant correlation
between RNFL thickness and Aβ SUVR. When assessing
macular RGCL, we observed only a slightly significant
reduction in the thickness when we compared patients
with clinical AD with the elderly control subjects and
participants with preclinical AD. The results were not
changed when the subjects with glaucoma and macular
degeneration were excluded.
The vascular contribution to the broad range of cog-
nitive impairment leading to AD has been recognised
[48, 49], including by professional societies providing
statements based on epidemiological evidence linking
loss of vascular function and development of dementia
[50]. Studies of associations of vascular function and
cognitive impairment are converging on the question
whether AD can be considered part of the spectrum of
vascular disease [51]. There is accumulating evidence
suggesting an association of arterial blood pressure, ar-
terial stiffness and reduced endothelial function with
AD [22, 52], but there have been conflicting findings in
the literature, and it is clearly not a simple relationship
with arterial blood pressure per se. Infusing hyperten-
sive doses of angiotensin II in APP/PS1-transgenic mice
produced a 100% increase in soluble Aβ in the brain
and a 25% reduction in cerebral microvessel density
[53]. We assessed central PP (systolic − diastolic) and
PWV and their association with Aβ SUVR. No significant
association or correlation was observed between these car-
diovascular parameters and neocortical Aβ scores.
Limitations of our study include that we did not have
neuroimaging data from our clinically confirmed AD
group, because we could not ethically justify scanning
these patients. It was anticipated that 80% of participants
with clinical AD would have high PET scores (>2). Addi-
tionally, there might be a false-positive rate within our
cohort (i.e., healthy elderly subjects with SUVR >1.4)
leading to classification as preclinical AD. Whereas this
would not affect the association between SUVR and reti-
nal vascular changes, future scans and recording will
elucidate the number of false-positives within the cohort.
We also acknowledge that a large proportion of our cog-
nitively healthy participants were receiving treatment for
systemic hypertension. In this age group, this is ex-
tremely common, but if our hypothesis is correct that
there is a link with arterial pulse waves and chronic
brain damage, then this treatment may be most likely
masking the effect.
Conclusions
This study demonstrates a significant correlation between
amplitude of retinal vascular pulsatility and neocortical
Aβ scores, independent of other risk factors. Arterial pul-
sation was increased while venous pulsation was reduced.
Future studies will further elucidate whether these bio-
markers have a correlation not only with cerebral Aβ
plaques but also with the development of subsequent clin-
ical dementia, because these participants are all being
followed longitudinally. If a clinical correlation is con-
firmed, although direct cause and effect cannot be certain,
screening of eyes in those considered at risk of AD may
aid in the development of an additional inexpensive ap-
proach for identifying increased risk as well as serving to
potentially monitor vascular function in these individuals.
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RGCL: Retinal ganglion cell layer; RNFL: Retinal nerve fibre layer; ROI: Region of
interest; RVP: Retinal venous pulsations; SBP: Systolic blood pressure;
SUVR: Standardised uptake value ratio; TIA: Transient ischaemic attack
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